COMP <GO>
CTAS vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Cintas Corporation (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: CTAS 8
— TMO 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CTAS
LAST: $218.07 (+2.47%) • MKT CAP: $86.59B
balance-sheet
14.53
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTAS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTAS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.70% | 9.30% | +20.40 | CTAS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 30.2x | 30.4x | -0.20 | CTAS | /valuation <GO> |
| Free Cash Flow Yield | 2.17% | 2.40% | -0.23 | TMO | /fcf-yield <GO> |
| Operating Margin | 23.10% | 17.40% | +5.70 | CTAS | /operating-margins <GO> |
| Net Profit Margin | 17.80% | 15.10% | +2.70 | CTAS | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 3.90% | +5.00 | CTAS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.81% | 0.24% | +0.57 | CTAS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 14.53 | 4.50 | +10.03 | CTAS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | CTAS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.3 | 62.9 | -3.60 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 0.94 | -0.01 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 40.3x | 36.3x | +4.00 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $86.59B | $262.22B | -$175.63B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTAS REV | TMO REV | CTAS GROSS % | TMO GROSS % | CTAS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.26B | $44.56B | 50.7% | — | $1.88B | $6.29B |
| FY 2024 | $10.34B | $42.88B | 50.0% | — | $1.76B | $7.27B |
| FY 2023 | $9.60B | $42.86B | — | — | $1.64B | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTAS // BETA 0.93
TMO // BETA 0.94